Atlanta, GANCT04563520Now EnrollingIRB Ready

Hemophilia A Clinical Trial in Atlanta, GA

Access cutting-edge hemophilia a treatment through this phase 3 clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.

Sponsored by Emory University

Quick Self-Assessment

See if you qualify for this Atlanta location

Preparing your pre-screening questions…

Expert Care in Atlanta

Access hemophilia a specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hemophilia a treatment provided free

Apply for This Atlanta Location

Check if you qualify for this hemophilia a clinical trial in Atlanta, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Atlanta

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Atlanta site if eligible
  4. 4Begin participation

About This Hemophilia A Study in Atlanta

The purpose of the aPCC-emicizumab safety study is to investigate the hemostatic efficacy as measured by thrombin generation, of a low personalized dose of aPCC (FEIBA) in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis.

Sponsor: Emory University

Who Can Participate

Inclusion Criteria

Moderately severe hemophilia A, defined as FVIII level \<0.05 IU/mL before development of an inhibitor
Age ≥6 years of age at time of informed consent
Documented on 2 occasions a high titer inhibitor (\>5 BU/mL) with a 72-hour washout within 2 years of enrollment
Parent/guardian (Legally Authorized Representative) or the patient has provided written informed consent
Adequate hematologic function (Hgb \>8 g/dL and platelet count \>100,000 µL)
Adequate hepatic function (total bilirubin ≤1.5 x ULN and both AST/ALT ≤3x ULN at screening (excluding known Gilbert's)
Adequate renal function (≤2.5 x ULN and CrCl ≥30 mL/min)

Exclusion Criteria

Inherited or acquired bleeding disorder other than hemophilia A excluding low VWF (\>30% VWF:RCo or VWF:GP1bm)
Had an active bleed requiring factor therapy at screening
Previous or current treatment for thromboembolic disease or signs of thromboembolic disease (excluding previously resolved line-associated thrombosis)
Had a surgical procedure 14 days before screening
Conditions that may increase the risk of bleeding or thrombosis
If the patient is treated with rFVIIa or aPCC seven days before screening
History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
Had current use of any medication other than emicizumab that could affect the coagulation system.
Known HIV infection with CD4 count \<200 cells/µL within 24 weeks before screening. Testing is not required if \<35 years of age.
Use of systemic immunomodulators at enrollment or planned use during the study
Participants who are at high risk for TMA (for example, have a previous medical/family history of TMA), in the investigator's judgment
Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose an additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Atlanta?

Yes, this clinical trial (NCT04563520) has an active research site in Atlanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hemophilia A Treatment Options in Atlanta, GA

If you're searching for hemophilia a treatment options in Atlanta, GA, this clinical trial (NCT04563520) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Atlanta research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced hemophilia a specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hemophilia a clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Hypertension Trials in Atlanta, GA

See all pulmonary hypertension clinical trials recruiting in Atlanta — not just this study.

Browse Pulmonary Hypertension Trials in Atlanta →

Browse More Trials by Condition

Pulmonary Hypertension TrialsHemophilia TrialsAll Conditions →

Ready to Join in Atlanta?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Atlanta, GA